Literature DB >> 18307853

Acceptance or rejection of prophylactic medicine in patients with migraine: a cross-sectional study.

Carianne M C Kol1, Frans Dekker, Arie Knuistingh Neven, Willem J J Assendelft, Jeanet W Blom.   

Abstract

Most patients with two or more migraine attacks per month do not use prophylactic medication. The aim of this study is to investigate how many patients use prophylaxis or would like to use them, and which aspects of migraine contribute to the choice to use prophylactic treatment. In a cross-sectional survey in three general practices, patients were selected who were diagnosed with migraine or had prescriptions for migraine medication. A questionnaire was sent to 283 patients and completed by 166 patients, of whom 15 were excluded. A total of 129 females and 22 males were included (median age 41 years). Most patients had two or more attacks per month (66.2%). Fifty-five per cent of patients with two or more attacks per month wanted to use prophylaxis; only 8% actually used this treatment. To get more insight into the ideas for or against prophylactic use, qualitative research is indicated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18307853      PMCID: PMC2233959          DOI: 10.3399/bjgp08X264063

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  10 in total

1.  A qualitative study of migraine involving patient researchers.

Authors:  Judith Belam; Gill Harris; David Kernick; Frances Kline; Krissy Lindley; Jayne McWatt; Annie Mitchell; Debbie Reinhold
Journal:  Br J Gen Pract       Date:  2005-02       Impact factor: 5.386

2.  Migraine in the United States: epidemiology and patterns of health care use.

Authors:  R B Lipton; A I Scher; K Kolodner; J Liberman; T J Steiner; W F Stewart
Journal:  Neurology       Date:  2002-03-26       Impact factor: 9.910

Review 3.  The preventive treatment of migraine.

Authors:  Marcelo E Bigal; Richard B Lipton
Journal:  Neurologist       Date:  2006-07       Impact factor: 1.398

Review 4.  Epidemiology of headache.

Authors:  B K Rasmussen
Journal:  Cephalalgia       Date:  2001-09       Impact factor: 6.292

5.  Incidence and determinants of migraine prophylactic medication in the Netherlands.

Authors:  H Rahimtoola; H Buurma; C C Tijssen; H G Leufkens; A C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2002-04-05       Impact factor: 2.953

6.  Migraine prevalence, disease burden, and the need for preventive therapy.

Authors:  R B Lipton; M E Bigal; M Diamond; F Freitag; M L Reed; W F Stewart
Journal:  Neurology       Date:  2007-01-30       Impact factor: 9.910

7.  Topiramate improves health-related quality of life when used to prevent migraine.

Authors:  Merle Diamond; Carl Dahlöf; George Papadopoulos; Walter Neto; S-C Wu
Journal:  Headache       Date:  2005-09       Impact factor: 5.887

8.  A six-item short-form survey for measuring headache impact: the HIT-6.

Authors:  M Kosinski; M S Bayliss; J B Bjorner; J E Ware; W H Garber; A Batenhorst; R Cady; C G H Dahlöf; A Dowson; S Tepper
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

9.  How do patients referred to neurologists for headache differ from those managed in primary care?

Authors:  Leone Ridsdale; Lucy V Clark; Andrew J Dowson; Laura H Goldstein; Linda Jenkins; Paul McCrone; Myfanwy Morgan; Paul T Seed
Journal:  Br J Gen Pract       Date:  2007-05       Impact factor: 5.386

10.  Propranolol in the management of recurrent migraine: a meta-analytic review.

Authors:  K A Holroyd; D B Penzien; G E Cordingley
Journal:  Headache       Date:  1991-05       Impact factor: 5.887

  10 in total
  8 in total

1.  Easing the pain: challenges and opportunities in headache management.

Authors:  David P B Watson
Journal:  Br J Gen Pract       Date:  2008-02       Impact factor: 5.386

2.  A proactive approach to migraine in primary care: a pragmatic randomized controlled trial.

Authors:  Antonia F H Smelt; Jeanet W Blom; Frans Dekker; M Elske van den Akker; Arie Knuistingh Neven; Frans G Zitman; Michel D Ferrari; Pim Assendelft
Journal:  CMAJ       Date:  2012-01-09       Impact factor: 8.262

3.  Prophylactic treatment of migraine by GPs: a qualitative study.

Authors:  Frans Dekker; Arie Knuistingh Neven; Boukje Andriesse; David Kernick; Michel D Ferrari; Willem J J Assendelft
Journal:  Br J Gen Pract       Date:  2012-04       Impact factor: 5.386

Review 4.  Key points in migraine prophylaxis: patient perspective.

Authors:  Domenico D'Amico; S J Tepper
Journal:  Neurol Sci       Date:  2009-05       Impact factor: 3.307

5.  Prophylactic treatment of migraine; the patient's view, a qualitative study.

Authors:  Frans Dekker; Arie Knuistingh Neven; Boukje Andriesse; David Kernick; Ria Reis; Michel D Ferrari; Willem J J Assendelft
Journal:  BMC Fam Pract       Date:  2012-03-09       Impact factor: 2.497

6.  Should I stay or should I go? A qualitative study exploring participation in a urology clinical trial.

Authors:  Mabel Leng Sim Lie; Jan Lecouturier; Christopher Harding
Journal:  Int Urogynecol J       Date:  2018-10-17       Impact factor: 2.894

7.  Prophylaxis of migraine: general principles and patient acceptance.

Authors:  Domenico D'Amico; Stewart J Tepper
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

8.  Migraine-preventive prescription patterns by physician specialty in ambulatory care settings in the United States.

Authors:  Hiroko Takaki; Daisuke Onozuka; Akihito Hagihara
Journal:  Prev Med Rep       Date:  2017-12-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.